

# Novocure (NVCR) presentation

2018 Wells Fargo Healthcare Conference  
September 6, 2018

patientforward



# forward-looking statements

This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives, including with respect to the development and commercialization of its lead product candidate, Optune, for a number of oncology indications. These forward-looking statements can be identified in this presentation by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words “expect”, “intend”, “anticipate”, “plan”, “may”, “should”, “would”, “could” or other words of similar meaning. These statements are based on assumptions and assessments made by Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. By their nature, forward-looking statements involve risk and uncertainty, and Novocure’s performance and financial results could differ materially from those expressed or implied in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2018, or in subsequent quarterly filings with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation. Novocure assumes no obligation to update or correct the information contained in this presentation, whether as a result of new information, future events or otherwise, except to the extent legally required.

The statements contained in this presentation are made as at the date of this presentation, unless some other time is specified in relation to them, and service of this presentation shall not give rise to any implication that there has been no change in the facts set out in this presentation since such date. Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the future financial performance of Novocure, except where expressly stated.

As of the date of this presentation, Optune is only FDA-approved for the treatment of adults with supratentorial glioblastoma, or GBM, and its approval for other indications is not certain. Novocure can provide no assurances regarding market acceptance of Optune or its successful commercialization, and can provide no assurances regarding the company’s results of operations or financial condition in the future. This presentation is for informational purposes only and may not be relied upon in connection with the purchase or sale of any security.

# Optune® indications for use and important safety information

## INDICATIONS

- Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
- Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.
- For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

## CONTRAINDICATIONS

- Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.
- Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.


# Optune® indications for use and important safety information

## WARNINGS AND PRECAUTIONS


- Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).
- Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.
- The most common ( $\geq 10\%$ ) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.
- The most common ( $\geq 10\%$ ) adverse events seen with Optune monotherapy were medical device site reaction and headache.
- The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.
- Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.
- If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

# electric fields exert forces on electrically polarized molecules


**GRAVITATIONAL FIELDS**  
exert force on masses




**MAGNETIC FIELDS**  
exert force on iron  
& other magnets



**ELECTRIC FIELDS**  
exert force on charges  
& polarized molecules



# Tumor Treating Fields uses electric fields to disrupt cell division



# the Optune® system

## ELECTRIC FIELD GENERATOR



Portable Tumor Treating Fields generator

## TRANSDUCER ARRAY


Sterile, single-use transducer arrays replaced every 3 days



Steve is an Optune user

In newly diagnosed GBM,

# Optune plus temozolomide provided an unprecedented long-term survival benefit




GBM, glioblastoma; TMZ, temozolomide; PFS, progression-free survival; ITT, intent-to-treat

1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA*. 2017;318(23):2306-2316.

2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized-clinical trial. *JAMA Oncol* 2018;4(4)495-504.

# dose response - more time on Optune predicted increased survival benefit





# 86%

of patients received a survival benefit from Optune because they used it more than half the time (n=388/450)

TMZ, temozolomide  
 Ram Z, Kim CY, Nicholas GA and Toms S on behalf of EF-14 investigators. Compliance and treatment duration predict survival in a phase 3 EF-14 trial of Tumor Treating Fields with temozolomide in patients with newly diagnosed glioblastoma. Presented at: 2017 Society for Neuro Oncology; November 16-19, 2017. San Francisco, CA. Oral presentation ACTR-27.

# five-year survival analysis in compliant patients



Ram Z, Kim CY, Nicholas GA and Toms S on behalf of EF-14 investigators. Compliance and treatment duration predict survival in a phase 3 EF-14 trial of Tumor Treating Fields with temozolomide in patients with newly diagnosed glioblastoma. Presented at: 2017 Society for Neuro Oncology; November 16-19, 2017; San Francisco, CA. Oral presentation ACTR-27.

# established commercial operations in six markets across three regions




Information above as of June 30, 2018

†Considers currently active markets: Germany, Switzerland, Austria and Israel

# continued growth in active patients

active patients at period end



14

CONSECUTIVE QUARTERS OF ACTIVE PATIENT GROWTH SINCE INITIAL PRESENTATION OF EF-14 DATA

8,000+

PATIENTS TREATED TO DATE GLOBALLY

# record quarterly revenue of \$61.5 million

global net revenues (USD in thousands)




60%

YEAR-OVER-YEAR REVENUE GROWTH Q2 2018 VS. Q2 2017

\$217

MILLION TRAILING TWELVE MONTH REVENUES

# advancing clinical pipeline



# completed pilot PANOVA trial in pancreatic cancer

A pilot, double arm, non-randomized, open-label study of Tumor Treating Fields (150 kHz) concomitant with gemcitabine and nab-paclitaxel for frontline treatment of pancreatic adenocarcinoma

- 40 patients (2 cohorts of 20 patients) with comparison to historical controls
- Data was presented at the ASCO 2016 Gastrointestinal Cancers Symposium in January 2016 and at the 107<sup>th</sup> Annual Meeting of the American Association of Cancer Research in April 2017

EFFICACY ENDPOINTS FOR SECOND COHORT	TTFIELDS WITH NAB-PACLITAXEL + GEMCITABINE <sup>1</sup>	NAB-PACLITAXEL + GEMCITABINE HISTORICAL RESULTS <sup>2</sup>
Median PFS	12.7 months	5.5 months
Median OS	Not yet reached	8.5 months
One-year survival rate	72%	35%
Partial response rate (PR)	40%	23%
Clinical benefit (PR plus stable disease)	87%	50%

Novocure, Ltd. Safety Feasibility and Effect of TTFIELDS (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2018 May]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01971281>. NLM Identifier: NCT01971281 **1**. Benavides M. et al. PANOVA: A phase II study of TTFIELDS (150kHz) concomitant with standard chemotherapy for front line therapy of advanced pancreatic adenocarcinoma In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Abstract CT130. **2**. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. *N Engl J Med*. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369

**novocure**<sup>TM</sup>

patientforward